Skip to main content
Home Home

User account menu

  • Log in

Main navigation

  • Home
  • Topics
    • Antimicrobials
    • Asthma
    • Biological medicines
    • COVID-19 medicines
    • Cardiovascular disease
    • Equity
    • Focus medicines
    • Gout
    • Hepatitis C
    • Menopause
    • Type 2 diabetes
    • Youth mental health
  • Resources
    • All education/search
    • Brand changes
    • Clinical articles
    • HAH Bulletins
    • Podcasts
    • Recorded webinars
    • Reflect & audit activities
    • Resource hubs
    • Videos
  • EPiC dashboard
    • Go to EPiC
    • Join EPiC
    • EPiC FAQ
    • EPiC Demo
    • About EPiC
  • News
    • Events
    • That's Interesting
    • From The Team

Education

  1. Home
  2. Search

The hub for all your learning resources.

Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.

Image of an older Māori man in a pharmacy
This item is over 2 years old; some content may no longer be current

Medicines and older Māori

2 minutes to Read + 43 minutes to Explore

Focusing on the experiences of older Māori in primary care, this course comprises four short videos, an independent reflection, downloadable posters and additional resources.

The course is endorsed by RNZCGP and CNA(NZ) and meets PCNZ recertification requirements. Reflection templates are included for you to complete.

Contributor
Dr Jo Hikaka
18 May 2021
  • Equity
  • Videos
  • Reflect & audit activities
HAH Applied
This item is over 2 years old; some content may no longer be current

Targeting optimal HbA1c level in type 2 diabetes using appropriate blood glucose lowering medicine

This Quality Improvement Activity enables you to review the glycaemic management of your type 2 diabetes patients and identify those who may benefit from initiation or intensification of blood glucose lowering medicines.

Good glycaemic control has a clear benefit on microvascular outcomes and if started early enough, on long-term macrovascular outcomes of coronary artery disease, stroke and peripheral vascular disease.

Contributor
He Ako Hiringa
3 May 2021
  • Diabetes
  • Reflect & audit activities
  • Equity
New way, this way, another way, that way
This item is over 2 years old; some content may no longer be current

Supporting patients to take the new diabetes meds: What you need to know

11 minutes to Read

Diabetes clinical nurse specialist Lisa Sparks discusses the place of empagliflozin and dulaglutide in treatment of type 2 diabetes, with emphasis on potential side effects, sick-day management and improving patient adherence.

Contributor
Lisa Sparks
30 April 2021
  • Diabetes
  • Clinical article
Meeting the needs of Māori
This item is over 2 years old; some content may no longer be current

Meeting the needs of Māori

20 minutes to Read

Māori attitudes to healthcare today are deeply rooted in New Zealand history. In this article, Deborah Bassett-Clarke discusses some reasons why the current model of pharmacy practice does not always meet the needs of Māori and may actually cause health inequities. Understanding these factors is an important first step to improving outcomes for Māori.

Contributor
Deborah Bassett-Clarke
30 April 2021
  • Equity
  • Clinical article
Bulletin #2
This item is over 2 years old; some content may no longer be current

Drivers of medicine access equity

1 minute to Read + 2 minutes to Delve

Medicine affordability is one of the five drivers of medicine access equity.

Up to 40 per cent of people continue to pay prescription copayments even though they are entitled to an exemption. No person or family should pay more than $100 per annum for subsidised medicines.

Contributor
He Ako Hiringa
30 April 2021
  • HAH Bulletins
  • Equity
Raised hands image
This item is over 2 years old; some content may no longer be current

Empagliflozin and dulaglutide: Your questions answered (1)

45 minutes to Delve

This list of Q&A reflects issues discussed in webinars held early in 2021.

The content has been edited, and reviewed by Waikato DHB endocrinologist/diabetologist Dr Ryan Paul.

Contributor
Dr Ryan Paul (Ngāti Maru)
23 April 2021
  • Diabetes
T2D - Needle Prick
This item is over 2 years old; some content may no longer be current

Starting empagliflozin in people on insulin and with good glycaemic control

4 minutes to Read

Your patient uses gliclazide and insulin but could still benefit from the additional cardiovascular and renal protections of empagliflozin. How would you manage the change in treatment? 

This case study is particularly relevant to prescribers. It originally appeared in the 3 March 2021 issue of New Zealand Doctor Rata Aotearoa and has been republished with permission.

Contributor
Penny Clark, Dr Linda Bryant
13 April 2021
  • Diabetes
  • Clinical article
Time for change
This item is over 2 years old; some content may no longer be current

Type 2 diabetes: Two medications offer fresh management paradigm

11 minutes to Read

Current management of type 2 diabetes includes two new classes of medication, SGLT2 inhibitors and GLP-1 receptor agonists, where clinically indicated. This article was published in the April 2021 edition of Kai Tiaki. It has been edited specifically for our nursing readership from an article that appeared in New Zealand Doctor and Pharmacy Today late in 2020. 

This article is endorsed by the College of Nurses Aotearoa (NZ) Inc.

Contributor
Dr Rinki Murphy, Lisa Sparks
9 April 2021
  • Diabetes
  • Clinical article
Hit It! Capture!
This item is over 2 years old; some content may no longer be current

New Capture tool takes the pain out of keeping track of learning

3 minutes to Read

Capture, a new online tool, will help He Ako Hiringa members keep track of what they’re learning online.

Clicking the Capture button at the bottom of each educational piece will create a record of the time taken to read, watch or listen to that content. Members will also be able to record their thoughts and reflections on the content, creating a Capture Record that can then be downloaded and used as a record of learning.

Contributor
He Ako Hiringa
1 April 2021
Bulletin #1
This item is over 2 years old; some content may no longer be current

Inequities in type 2 diabetes

1 minute to Read + 2 minutes to Delve

Health inequities in the detection and management of diabetes and its associated health outcomes are significant concerns in New Zealand. The first step to addressing inequitable health outcomes is knowing that they exist.

Contributor
He Ako Hiringa
30 March 2021
  • HAH Bulletins
  • Equity
  • Diabetes
This item is over 2 years old; some content may no longer be current

What's new with type 2 diabetes care in 2021?

1 minute to Read + 65 minutes to Watch

In this webinar, Dr Ryan Paul discusses the changes to type 2 diabetes care in 2021, including when and how to use SGLT2 inhibitors and GLP-1 agonists.

Downloadable empagliflozin patient information and a recent slide presentation can be found within this article.

Contributor
Dr Ryan Paul (Ngāti Maru)
4 March 2021
  • Diabetes
  • Recorded webinars
This item is over 2 years old; some content may no longer be current

Can you say empagliflozin?

If you're having trouble pronouncing the name of the newly funded SGLT2 inhibitor for type 2 diabetes, you're not the only one! Watch our video guide to learn how to pronounce empagliflozin. 

Contributor
He Ako Hiringa
3 March 2021
  • Videos
  • Diabetes

Pagination

  • « First First page
  • ‹ Previous Previous page
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next › Next page
  • Last » Last page
Home Home

Contact Us

Suite B, 2/20 Augustus Terrace, Parnell, Auckland 1052

PO Box 37590, Parnell, Auckland 1151

Support

09 488 4286

admin@akohiringa.co.nz

(9-5pm Mon-Fri)

Contact us

About us

Terms & Policies

  • Conditions for Use

Supported by

Pharmac

© Matui Limited. All rights reserved.

Developed by Matui Limited and brought to life by Communica.